Immunoglobulin A Nephropathy
30
7
15
7
Key Insights
Highlights
Success Rate
70% trial completion
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
10.0%
3 terminated out of 30 trials
70.0%
-16.5% vs benchmark
30%
9 trials in Phase 3/4
114%
8 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (30)
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
First in Human Study to Assess Safety of VIS649 in Healthy Subjects
Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
Safety and Efficacy Study of VIS649 for IgA Nephropathy
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
A Study of Zigakibart in Adults With IgA Nephropathy
Study of Ravulizumab in Pediatric Participants With Primary IgAN
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy
Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
Atrasentan in Patients With Proteinuric Glomerular Diseases
A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US